Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria

D. Mohanty, K. Ghosh, A. V. Pathare, D. Karnad

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background & objectives: Mortality due to Plasmodium falciparum infection remains high in India, hence any modality of treatment which can improve the outcome of this disease is worth exploring. The present study was undertaken to see whether addition of an oral iron chelator, deferiprone (L1) to the conventional treatment regime for P. falciparum infection improves the clinical course and final outcome. Methods: In this prospective, randomised double blind trial, 45 consecutive patients with P. falciparum infection were randomised into two groups. Patients in Group I (control group, 21 patients) received standard quinine and doxycycline therapy along with supportive therapy and placebo capsules for 10 days. Patients in Group II (24 patients) received the same treatment as Group I but in place of placebo capsule received deferiprone capsules 75 mg/kg/day in 12 hourly divided doses. The parameters evaluated included the time taken in resolution of parasitaemia, fever and coma, differences in final outcome i.e., death or other severe complications, and side effects and deferiprone tolerance. Results: Four patients in Group I and two in Group II died (P>0.05). The resolution of fever and coma was significantly faster in Group II (P

Original languageEnglish
Pages (from-to)17-21
Number of pages5
JournalIndian Journal of Medical Research
Volume115
Issue numberJAN.
Publication statusPublished - 2002

Fingerprint

Falciparum Malaria
Capsules
Plasmodium falciparum
Malaria
Quinine
Doxycycline
Chelating Agents
Coma
Fever
Therapeutics
Iron
Placebos
Parasitemia
deferiprone
India
Control Groups
Mortality

Keywords

  • Adjuvant therapy
  • Deferiprone
  • Falciparum malaria
  • Iron chelation
  • Plasmodium falciparum

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria. / Mohanty, D.; Ghosh, K.; Pathare, A. V.; Karnad, D.

In: Indian Journal of Medical Research, Vol. 115, No. JAN., 2002, p. 17-21.

Research output: Contribution to journalArticle

Mohanty, D. ; Ghosh, K. ; Pathare, A. V. ; Karnad, D. / Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria. In: Indian Journal of Medical Research. 2002 ; Vol. 115, No. JAN. pp. 17-21.
@article{b6bb566217a24471b5e2465b3638839f,
title = "Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria",
abstract = "Background & objectives: Mortality due to Plasmodium falciparum infection remains high in India, hence any modality of treatment which can improve the outcome of this disease is worth exploring. The present study was undertaken to see whether addition of an oral iron chelator, deferiprone (L1) to the conventional treatment regime for P. falciparum infection improves the clinical course and final outcome. Methods: In this prospective, randomised double blind trial, 45 consecutive patients with P. falciparum infection were randomised into two groups. Patients in Group I (control group, 21 patients) received standard quinine and doxycycline therapy along with supportive therapy and placebo capsules for 10 days. Patients in Group II (24 patients) received the same treatment as Group I but in place of placebo capsule received deferiprone capsules 75 mg/kg/day in 12 hourly divided doses. The parameters evaluated included the time taken in resolution of parasitaemia, fever and coma, differences in final outcome i.e., death or other severe complications, and side effects and deferiprone tolerance. Results: Four patients in Group I and two in Group II died (P>0.05). The resolution of fever and coma was significantly faster in Group II (P",
keywords = "Adjuvant therapy, Deferiprone, Falciparum malaria, Iron chelation, Plasmodium falciparum",
author = "D. Mohanty and K. Ghosh and Pathare, {A. V.} and D. Karnad",
year = "2002",
language = "English",
volume = "115",
pages = "17--21",
journal = "Indian Journal of Medical Research",
issn = "0971-5916",
publisher = "Indian Council of Medical Research",
number = "JAN.",

}

TY - JOUR

T1 - Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria

AU - Mohanty, D.

AU - Ghosh, K.

AU - Pathare, A. V.

AU - Karnad, D.

PY - 2002

Y1 - 2002

N2 - Background & objectives: Mortality due to Plasmodium falciparum infection remains high in India, hence any modality of treatment which can improve the outcome of this disease is worth exploring. The present study was undertaken to see whether addition of an oral iron chelator, deferiprone (L1) to the conventional treatment regime for P. falciparum infection improves the clinical course and final outcome. Methods: In this prospective, randomised double blind trial, 45 consecutive patients with P. falciparum infection were randomised into two groups. Patients in Group I (control group, 21 patients) received standard quinine and doxycycline therapy along with supportive therapy and placebo capsules for 10 days. Patients in Group II (24 patients) received the same treatment as Group I but in place of placebo capsule received deferiprone capsules 75 mg/kg/day in 12 hourly divided doses. The parameters evaluated included the time taken in resolution of parasitaemia, fever and coma, differences in final outcome i.e., death or other severe complications, and side effects and deferiprone tolerance. Results: Four patients in Group I and two in Group II died (P>0.05). The resolution of fever and coma was significantly faster in Group II (P

AB - Background & objectives: Mortality due to Plasmodium falciparum infection remains high in India, hence any modality of treatment which can improve the outcome of this disease is worth exploring. The present study was undertaken to see whether addition of an oral iron chelator, deferiprone (L1) to the conventional treatment regime for P. falciparum infection improves the clinical course and final outcome. Methods: In this prospective, randomised double blind trial, 45 consecutive patients with P. falciparum infection were randomised into two groups. Patients in Group I (control group, 21 patients) received standard quinine and doxycycline therapy along with supportive therapy and placebo capsules for 10 days. Patients in Group II (24 patients) received the same treatment as Group I but in place of placebo capsule received deferiprone capsules 75 mg/kg/day in 12 hourly divided doses. The parameters evaluated included the time taken in resolution of parasitaemia, fever and coma, differences in final outcome i.e., death or other severe complications, and side effects and deferiprone tolerance. Results: Four patients in Group I and two in Group II died (P>0.05). The resolution of fever and coma was significantly faster in Group II (P

KW - Adjuvant therapy

KW - Deferiprone

KW - Falciparum malaria

KW - Iron chelation

KW - Plasmodium falciparum

UR - http://www.scopus.com/inward/record.url?scp=0035986016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035986016&partnerID=8YFLogxK

M3 - Article

VL - 115

SP - 17

EP - 21

JO - Indian Journal of Medical Research

JF - Indian Journal of Medical Research

SN - 0971-5916

IS - JAN.

ER -